As of April 29,
2022, NKCL Bio Group Inc. has announced that it had acquired three new patents:
a polymer nanoparticle based cancer vaccine composition, a dendritic cell therapeutics
for cancer, and a composition for preventing and treating cancer.
obtained this time are related to 'composition for cancer vaccine
manufacturing' and 'cell therapy composition for cancer treatment', including
cell cancer, and was promoted in the form of industry-university cooperation (Inventor_University,
Proprietor_Company) for stable research and rapid commercialization based on
the research ability of the university and the commercialization ability of the
One patent is
regarding a 'polymer nanoparticle based cancer vaccine composition' with
excellent anticancer immunotherapeutic effects that can maximize various anti-cancer
effects without providing external information about the patient's cancer
(cancer antigen information).
explanation) The process that NK immune cells in our body effectively attack
and treat cancer cells
As shown in the
figure above, according to the present invention, it is an immunoadjuvant that
stimulates Tall-Like Receptors (TLR) to secrete various cytokines and delivers
short interfering RNA that suppresses the immune response to dendritic cells
simultaneously, thereby treating cancer with the effects of increasing the
cancer treatment more than 8 times compared to the existing anti-cancer
immunotherapy and can be used in the treatment of various cancers and diseases.
NKCL Bio Group
Inc, which has secured its own technology for NK cell culture and succeeded in
developing and operating an automatic culture system, has been able to be one
step closer to developing a full-fledged NK cell treatment drug with this
In addition, the other patent acquired is for a dendritic cell cancer
treatment using a 'heparin-binding compound', which is known to inhibit the
occurrence of blood clots derived from a COVID-19 vaccine or therapeutic agent.
It is expected to open a new path not only for cell therapy but also for the
development of therapeutics that can cope with new pandemics.
The basic principle of NK cell therapy is a gene technology for
isolating and cultivating NK cells, which are immune cells, from the peripheral
blood of cancer patients and after strengthening immunity by cultivating NK
cells, the patient is then injected with their own immune-enhanced NK cells.
An official from NKCL Bio Group Inc. has said, “Through the
acquisition of these patents, our research achievements have been officially
recognized, and we will actively promote the commercialization of research
results in the future.”
NKCL Bio Group Inc. is a proprietor for 'NK cell culture medium addition kit
and NK cell culture method using the kit' (Korean, Japanese, Chinese patents acquired/US,
European patent pending), 'Cultivating allogeneic immune cells', and ‘cosmetic
composition using additive composition’ etc., a total of 9 patents.